|
WO2021080531A1
|
|
A process for the preparation of dry powder compositions for inhalation
|
|
WO2021066772A1
|
|
Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
|
|
WO2020055360A2
|
|
The parenteral composition comprising carfilzomib
|
|
WO2020101596A2
|
|
A capsule composition comprising sunitinib
|
|
WO2020055359A2
|
|
Oral dosage form of sorafenib tosylate
|
|
WO2020101597A2
|
|
Capsule compositions comprising tyrosine-kinase inhibitors
|
|
WO2020055357A2
|
|
Inhalation compositions comprising phosphodiesterase-4 inhibitor
|
|
WO2020018058A2
|
|
The injectable micronized human insulin
|
|
WO2020055356A2
|
|
Inhalation compositions comprising anti-bacterial agents
|
|
WO2020013793A2
|
|
Inhalation compositions comprising dopamine agonists
|
|
WO2020018053A2
|
|
The tablet comprising dasatinib
|
|
TR201820952A2
|
|
GRANULOCYTE COLONY A COMBINATION WITH A STIMULATING FACTOR
|
|
TR201712424A2
|
|
DRY POWDER INHALATION COMPOSITIONS
|
|
US2015202297A1
|
|
Dry powder inhalers comprising a carrier other than lactose and a ternary component
|
|
US2015150802A1
|
|
Dry powder inhaler compositions comprising long acting muscarinic antagonists
|
|
US2015174345A1
|
|
Blister advancement mechanism comprising an actuator plate
|
